San Antonio—Emtora Biosciences, a San Antonio biotech startup formerly known as Rapamycin Holdings, is planning to test its drug, eRapa, as a treatment for a rare genetic disease known as Familial Adenomatous Polyposis (FAP).
Emtora plans to begin a Phase 2a trial in late 2019 for the condition, which affects 60,000 people in the United States, the company said in a news release. For those with the condition, which is typically inherited, hundreds of polyps begin forming in the colon and rectum of a patient in his or her teenage years. Those growths are benign when they form, but can… Read more »
UNDERWRITERS AND PARTNERS